Wednesday, October 29, 2008: 9:15 AM-11:45 AM
River Exhibition Hall
Level 1
Sheraton Chicago Hotel & Towers
1.1
A Candidate Gene Analysis of Methylphenidate Response in ADHD
James J. McGough, M.D.
UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA
James McCracken, M.D.
University of California at Los Angeles/Neuroscience, Psychiatry, and Biobehavior, Los Angeles, CA
Sandra K. Loo, Ph.D.
University of California Los angeles, Los angeles, CA
1.2
Elevated Resting Glutamate in the Striatum and Prefrontal Cortex of Dopamine D4 Receptor Knockout Mice
Paul E.A. Glaser, M.D., Ph.D.
University of Kentucky, Lexington, KY
Theresa C. Thomas, Ph.D.
, Lexington, KY
David K. Grandy, Ph.D.
Oregon Health and Science University, Portland, OR
Greg A. Gerhardt, Ph.D.
University of Kentucky, Lexington, KY
1.3
Dissociation Between Verbal and Spatial Working Memory Functioning in ADHD
Sinead M. Rhodes, B.A., M.A., Ph.D.
University of Stirling, Stirling, Scotland
Joanne Park, B.A.
Sarah Seth, MBchB
University of Dundee, Dundee Scotland
Helen Smith, MBchB
David Coghill, M.D.
Centre for Child Health, Dundee Scotland
1.4
Psychometric Properties of the Life Participation Scale for Adults Assessing Deficits in Adaptive Functioning
Keith Saylor, Ph.D., Sc.M.
NeuroScience, Inc., Herndon, VA
Virginia Sutton, Ph.D.
, Memphis, TN
Christine Moore, Ph.D.
, Kennersville, NC
1.5
A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Atomoxetine Hydrochloride in Child Outpatients with ADHD in Japan
Michihiro Takahashi, M.D.
Lilly Research Laboratories Japan, Kobe Japan
Taro M. Gotoh, M.D.
Lilly Research Laboratories Japan, Kobe Japan
Yasushi Takita
Lilly Research Laboratories Japan, Kobe Japan
Albert J. Allen, M.D., Ph.D.
Lilly Research Laboratories, Indianapolis, IN
1.6
ADHD in Preschool Children: An Investigation of Validation Based on Visual Attention Performance
Mini Tandon, D.O.
Washington University School of Medicine, Saint Louis, MO
Xuemei Si, M.P.H., M.S.
Andy Belden, Ph.D.
Washington University School of Medicine, Saint Louis, MO
Joan Luby, M.D.
Washington University School of Medicine, St. Louis, MO
1.7
Adolescent Psychiatric Outcome of Urban Children Diagnosed with ADHD
Virginia A. De Sanctis, M.A.
Mount Sinai School of Medicine, New York, NY
Jeffrey Newcorn, M.D.
Mount Sinai School of Medicine, New York, NY
Jeffrey M. Halperin, Ph.D.
Queens College, City University of New York, Flushing, NY
1.8
ABT-089, A Neuronal Nicotinic Receptor Partial Agonist, Improves Cognition in Adults with ADHD
Walid M. Abi-Saab, M.D.
Abbott Laboratories, Abbott Park, IL
George Apostol, M.D.
Abbott Laboratories, Evanston, IL
Jeffrey Baker, Ph.D.
Yaqin Wang, Ph.D.
Mario Saltarelli, M.D., Ph.D.
1.9
Correlation Analyses of the Conners' Adult ADHD Rating Scale and the Liebowitz Social Anxiety Scale Administered to Adults with ADHD and Comorbid Social Anxiety Disorder Following Atomoxetine Treatment
Lenard Adler, M.D.
New York University School of Medicine, New York, NY
Michael Liebowitz, M.D.
Meihua Qiao, M.S.
Millie Hollandbeck, B.S.
Todd M. Durell, M.D.
Eli Lilly and Company, Indianapolis, IN
1.10
A Dose-Optimization Study of the Efficacy, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years with ADHD
Robert L. Findling, M.D.
University Hospitals Case Medical Center, Cleveland, OH
Lawrence Ginsberg, M.D.
Red Oak Psychiatry Associates, Houston, TX
Rakesh Jain, M.D.
R/D Clinical Research, Inc, Lake Jackson, TX
Joseph Gao, Ph.D.
Shire Development, Inc., Wayne, PA
Cynthia Richards, M.D.
Shire Development, Inc., Wayne, PA
1.11
Efficacy and Safety of Quetiapine in Adolescents with Schizophrenia: A 6-Week, Double-Blind, Randomized, Placebo-Controlled Trial
Robert L. Findling, M.D.
University Hospitals Case Medical Center, Cleveland, OH
Kathleen Kline, M.D.
Kathleen McKenna, M.D.
, Chicago, IL
Willie Earley
, Wilmington, DE
Jill Stankowski, M.S.
Tracy Aviles, M.S.
Sanjeev Pathak, M.D.
1.12
Suicidal Behavior in Children and Adolescents with First Episode Psychosis
Tatiana Falcone, M.D.
Cleveland Clinic, Shaker Heights, OH
Erin Carlton, B.S.
Barry Simon, M.D.
, Solon, OH
Damir Janigro, Ph.D.
Leenu Mishra, M.D.
The Cleveland Clinic, Cleveland, OH
Kathleen Franco, M.D.
Cleveland Clinic Foundation, Cleveland, OH
1.13
Inflammatory Markers in Children with Psychosis: Implications for the Blood Brain Barrier
Tatiana Falcone, M.D.
Cleveland Clinic, Shaker Heights, OH
Erin Carlton, B.S.
Kathleen Franco, M.D.
Cleveland Clinic Foundation, Cleveland, OH
Adele Viguera, M.D.
Barry Simon, M.D.
, Solon, OH
Damir Janigro, Ph.D.
1.14
Predicting Substantial Weight Gain in Olanzapine-Treated Adolescents with Schizophrenia or Bipolar Disorder
Ludmila A. Kryzhanovskaya, M.D.
Eli Lilly and Company, Indianapolis, IN
Ilya A. Lipkovich, Ph.D.
Carol Robertson-Plouch
Lilly Corporate Center, Indianapolis, IN
Wen Xu, Ph.D.
Eli Lilly and Company, Indianapolis, IN
Susan B. Watson, Ph.D.
Mauricio Tohen, M.D., Dr.P.H.
1.15
Patient Assessed Quality of Life (PQ-LES-Q) vs. Clinician Assessment (PANSS, CGI) in a Trial of Aripiprazole in Adolescent Patients with Schizophrenia
Stephen R. Wisniewski, Ph.D.
University of Pittsburgh, Pittsburgh, PA
Mirza Ali, Ph.D.
Otsuka Pharmaceutical Development and Commercialization, Inc., Rockville USA
Na Jin, M.S.
Otsuka Pharmaceutical Development and Commercialization, Inc., Rockville USA
Richard Whitehead, B.S.
Otsuka America Pharmaceutical, Inc., Rockville, MD
Edward Kim, M.D., M.B.A.
Bristol-Myers Squibb, Plainsboro, NJ
Margaretta Nyilas, M.D.
Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ
William Carson, M.D.
Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ
Taro Iwamoto, Ph.D.
Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ
Andrei Pikalov, M.D., Ph.D.
Otsuka America Pharmaceutical, Inc., Rockville, MD
1.16
Pre-Incarceration Violence Encountered by Youth in São Paulo, Brazil
Susan Huculak, M.A.
John D. McLennan, M.D., FRCPC, Ph.D.
University of Calgary, Calgary, AL
Fatima Rigato, M.D., M.S.C.
Isabel Bordin, M.D., Ph.D.
1.17
Youth Re-Engagement in School Post-Incarceration in São Paulo, Brazil
Karolina Kowalewski
University of Calgary, Calgary, AB
John D. McLennan, M.D., FRCPC, Ph.D.
University of Calgary, Calgary, AL
Fatima Rigato, M.D., M.S.C.
Isabel Bordin, M.D., Ph.D.
1.18
Is the CBCL-PTSP Scale Related to Dysregulated Temperament?
Kendra C. Appe
University of Vermont College of Medicine, Burlington, VT
Lynsay Ayer, B.A.
, South Burlington, VT
David Rettew, M.D.
University of Vermont College of Medicine, Burlington, VT
Robert Althoff, M.D., Ph.D.
University of Vermont, Burlington, VT
James J. Hudziak, M.D.
Vermont Center For Children, Youth, and Families, Burlington, VT
1.19
Youth Psychiatric Emergency Room Use: A Focus on Youth with Depression and/or Disruptive Behavior Disorder Diagnoses
Carol Rockhill, M.D.
University of Washington, Bellevue, WA
Richard K. Ries, M.D.
Joan E. Russo, Ph.D.
Dept. of Psychiatry, University of Washington, Box 356560, Seattle, WA
1.20
The Continuous Performances and Behavioral Problems of Children with ADHD and Borderline Intelligence
Cheol-Soon Lee, M.D.
Gyeongsang National University Hospital, Jinju, Gyeongsangnamdo
Sojin Lee
Gyeongsang National University, Jinju South Korea
Sungnam Kim
Gyeongsang National University, Jinju South Korea
Jiyon Son
Gyeongsang National University, Jinju South Korea
1.21
Adolescents Diagnosed with ADHD in Childhood: Substance Use as a Function of Stimulant Medication
Seth C. Harty, M.S.
City University of New York, New York, NY
Jeffrey M. Halperin, Ph.D.
Queens College, City University of New York, Flushing, NY
Carlin Miller, Ph.D.
, Windsor, ON
Iliyan S. Ivanov, M.D.
Mount Sinai School of Medicine, New York, NY
Jeffrey Newcorn, M.D.
Mount Sinai School of Medicine, New York, NY
1.22
Association of Dopamine System Gene Polymorphisms with ADHD and Pediatric Bipolar Disorder
Dylan A.H. Alegría, M.S.
CIBSR, Stanford, CA
Kiki Chang, M.D.
Stanford University School of Medicine, Stanford, CA
Meghan E. Howe, M.S.W.
Stanford University, Stanford, CA
Xiaoyan Lin
Chun Liao, B.S.
Fawad Malik, M.D.
Joachim Hallmayer, M.D.
Stanford University, Stanford, CA
1.23
Does Childhood ADHD Predict Later Psychoactive Substance Use Disorder and Alcohol Use Disorder? A Meta-Analysis
Troy H. Climans, B.S.
The Hospital for Sick Children; University of Toronto, Toronto, ON
Emanuela Yeung, B.S.
Erin Lillie, B.S.
Jennifer Crosbie, Ph.D.
The Hospital for Sick Children, Toronto, ON
Russell Schachar, M.D., F.R.C.P.
University of Toronto, Toronto, ON
Alice Charach, M.D.
The Hospital for Sick Children, Toronto, ON
1.24
Lisdexamfetamine Dimesylate Demonstrated Efficacy throughout the Day up to 13 Hours in an Analog Classroom Study in Children with ADHD
Sharon Wigal, Ph.D.
University of California, Irvine, Irvine, CA
Scott Kollins, Ph.D.
Duke University, Durham, NC
Liza Squires, M.D.
Shire Development, Inc., Wayne, PA
Ann C. Childress, M.D.
Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, NV
1.25
Effects of Atomoxetine on High-Risk Behavior and Health-Related Quality of Life in Adolescents with ADHD
Linda Wietecha, M.S.
Eli Lilly and Company, Indianapolis, IN
David Williams, M.S.
Eli Lilly and Company, Carmel, IN
Keith Saylor, Ph.D., Sc.M.
NeuroScience, Inc., Herndon, VA
Michael Greenbaum, M.D.
, Long Grove, IL
Kory Schuh, Ph.D.
1.26
Effects of Atomoxetine and Behavior Therapy on the School and Home Functioning of Elementary School Children with ADHD
James G. Waxmonsky, M.D.
SUNY at Buffalo, Buffalo, NY
Daniel A. Waschbusch, Ph.D.
William E. Pelham Jr., A.B.P.P., Ph.D.
Center for Children and Families, Buffalo, NY
Lillian Dragnac-Cardona, M.S.
1.27
Correlates of ADHD Comorbidity among Adolescent Smokers
Himanshu P. Upadhyaya, M.D.
Eli Lilly, Houston, TX
Gregory Gilbert
Medical University of South Carolina, Charleston, SC
Kevin M. Gray, M.D.
Medical University of South Carolina, Charleston, SC
Matthew J. Carpenter, Ph.D.
Medical University of South Carolina, Charleston, SC
Terri Randall, M.D.
Medical University of South Carolina, Charleston, SC
Deborah Deas, M.D., M.P.H.
Institute of Psychiatry, Charleston, SC
1.28
Association of DRD4 and DAT 1 with ADHD: a Follow-up Study
Yanki Yazgan, M.D.
Marmara University Hospital, Istanbul Turkey
Selin Unal
Eda Tahir Turanli
Beril Taskin, M.D.
Aytul Karabekiroglu, M.D.
Duygu Bicer, M.D.
Aysegul Selcen Guler, M.D.
Nusin Elci, M.D.
Philip J. Asherson, MBBS, Ph.D.
MRC Social Genetic and Developmental Psychiatry, London United Kingdom
Ceyda Dedeoglu, M.A.
1.29
Persistence of Treatment in ADHD: Not from First Medication But From Patient Enrollment
Jun-Heon Park, M.D.
Kyung-Hee University Medical Center, Seoul South Korea
Geon-Ho Bahn, M.D., Ph.D.
Kyung-Hee University Hospital, Seoul Korea
Se-Young Jin, M.D.
Kyung-Hee University Hospital, Seoul South Korea
1.30
Intra-Subject Variability Is Related to Parental Ratings of ADHD and Executive Function Behaviors in Latino Children
Maria A. Mairena
New York University, New York, NY
Cristina Dominguez-Martin, Ph.D.
Complejo Asistencial de Zamora, Zamora Spain
Lorena Gomez-Guerrero, M.D.
Hospital Provincial de Pontevedra, Santiago de Compostela (La Coruña) Spain
Adriana DiMartino, M.D.
New York University Child Study Center, New York, NY
Eva Petkova, Ph.D.
New York University, New York, NY
Benard Dreyer, M.D.
New York University School of Medicine, New York, NY
Alan Mendelsohn, M.D.
New York University School of Medicine, New York, NY
Philip Reiss, Ph.D.
New york University School of Medicine, New York, NY
Peter Isquith, Ph.D.
Dartmouth Medical School, Rockville, MD
Gerard Gioia, Ph.D.
Children's National Medical Center, Rockville, MD
F. Xavier Castellanos, M.D.
New York University Child Study Center, New York, NY
1.31
Comorbidity of Bipolar Disorder in Children and Adolescents with ADHD
Melek G. Lus, M.D.
, Istanbul Turkey
Nahit M. Mukaddes, M.D.
University of Istanbul, Istanbul Turkey
1.32
Consistent Efficacy of Lisdexamfetamine Dimesylate on Individual Symptom Items of the Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale and ADHD Rating Scale in Two Randomized, Double-Blind, Placebo-Controlled Trials
Ann C. Childress, M.D.
Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, NV
Scott Kollins, Ph.D.
Duke University, Durham, NC
Mohamed Hamandi, M.S.
Shire Development, Inc., Wayne, PA
Bryan Dirks, M.D.
Shire Development, Inc., Wayne, PA
Srinivas Tetali, M.D.
Shire Development, Inc., Wayne, PA
Antonella Favit, M.D., Ph.D.
, Wayne, PA
Joseph Biederman, M.D.
Massachusetts General Hospital, Boston, MA
1.33
Substantiating the Need for Fluency Items in Rating Scales
Shirin Ansari, Ph.D.
Center for Learning & Behavioral Solutions, Inc., Irvine, CA
Gregory Koch
Center for Learning & Behavioral Solutions, Inc., Irvine, CA
James Swanson, Ph.D.
University of California at Irvine Child Development Center, Irvine, CA
David Brown, Ed.D.
1.34
Relationship Between Atomoxetine Plasma Concentration, Treatment Response, and Tolerability in ADHD and Comorbid Oppositional Defiant Disorder
Philip Hazell, FRANZCP, MBChB, Ph.D.
University of Sydney, Concord West, NSW
Katja Becker, M.D.
Central Institute of Mental Health, Mannheim Germany
Leannart von Wendt
Hyks Lasten ja Nuorten Sairaal, Helsinki Finland
Paula T. Trzepacz, M.D.
Eli Lilly and Company, Indianapolis, IN
Linda Tabas
Eli Lilly and Company, Indianapolis, IN
Leslie M. Schuh, Ph.D.
Eli Lilly and Company, Indianapolis, IN
Jennifer Witcher, Ph.D.
Eli Lilly and Company, Indianapolis, IN
Amanda Long
Eli Lilly and Company, Indianapolis, IN
George Ponsler, M.S.
Eli Lilly and Company, Indianapolis, IN
Yoko Tanaka, Ph.D.
Eli Lilly and Company, Indianapolis, IN
Ralf W. Dittmann, M.D., Ph.D.
Lilly Deutschland and University of Hamburg, Bad Homburg Germany
1.35
Latent Class Structure of Conners' Parent Rating Scales: Oppositional Subscale
Ana V. Kuny, B.A.
University of Vermont, Burlington, VT
Robert Althoff, M.D., Ph.D.
University of Vermont, Burlington, VT
William E. Copeland, Ph.D.
Duke University Medical Center, Durham, NC
Toos C.E.M. Van Beijsterveldt, Ph.D.
Vrije Universiteit, Amsterdam Netherlands
Dorret I. Boomsma, Ph.D.
Vrije Universiteit, Amsterdam Netherlands
James J. Hudziak, M.D.
Vermont Center For Children, Youth, and Families, Burlington, VT
1.36
Early Onset Conduct Disorders in Adolescents: Common and Gender-Specific Factors
Jean M. Toupin, Ph.D.
University of Sherbrooke, Sherbrooke, PQ
Yann D. Le Corff, M.A.
University of Sherbrooke, Sherbrooke, PQ
Robert Pauze, Ph.D.
Michele Dery, Ph.D.
1.37
Behavioral Health Specialty Care among Medicaid Enrolled Children Receiving Antipsychotic Medications
Emily N. Harris, M.D., M.P.H.
University of Pittsburgh Medical Center, Pittsburgh, PA
Bradley Stein, M.D., Ph.D.
University of Pittsburgh School of Medicine, Pittsburgh, PA
Mark Sobero, M.S.
Community Care Behavioral Health Organization, Pittsburgh, PA
1.38
Child Mental Health Waitlists: A Pilot Study in Ontario, Canada
Karolina Kowalewski
John D. McLennan, M.D., FRCPC, Ph.D.
University of Calgary, Calgary, AL
Charlotte Waddell, M.D., M.S.C.
Mary Perry, Ph.D., R.N.
John Lavis, M.D., Ph.D.
1.39
The Costs of Pervasive Developmental Disorders: Costs-of-Illness in Sardinia, Italy
Manuela Testa, M.D.
University of Cagliari, Cagliari Italy
Laura Anchisi, M.D.
Child Neuropsychiatry, Cagliari Italy
Paola Atzori, M.D.
Child Neuropsychiatry, Cagliari Italy
Gianluigi Melis, M.D.
Child Neuropsychiatry, Cagliari Italy
Massimo Brunetti, Ph.D.
Centro per la Valutazione dell'Efficacia dell'Assistenza Sanitaria, Modena Italy
Giuseppe Doneddu, M.D.
° “G.Brotzu” Hospital, Cagliari, Italy, Cagliari Italy
Alessandro Zuddas, M.D.
Department Neuroscience, University of Cagliari, Cagliari Italy
1.40
An Assessment of the Psychometric Properties of Lithuanian Versions of American Adolescent Pathological Gambling Screening Instruments (DSM-IV-MR-J and SOGS-RA)
David Freedman, M.D.
Kaunas University of Medicine, Kaunas Lithuania
Norbert Skokauskas Jr., M.D., Ph.D.
Trinity Centre for Health Sciences, St. Jame's Hospital,, Dublin Ireland
1.41
Phenomenology of Pre-Pubescent Drug Use in Substance-Dependent Youths
Luis Felipe Amunategui, Ph.D.
University Hospitals of Cleveland Case Medical Center, Cleveland, OH
Maryellen Davis, M.D.
, Berea, OH
Michelle Shea, B.A.
Casey Onder, B.A.
Justina Baryak, B.S.
Jihad Jaber, B.A.
Rebecca Ionescu, B.A.
Maria Pagano, Ph.D.
1.42
Comorbidity in Adolescents with Substance Use Disorders
Tugba Bahadir, M.D.
Marmara University Hospital, Istanbul Turkey
Semra Ulusan, M.D.
Marmara University Hospital, Istanbul Turkey
Sema Olcer, M.D.
Marmara University Hospital, Istanbul Turkey
Zeynep Yaman, M.D.
Marmara University Hospital, Istanbul Turkey
Nese Fis, M.D.
Marmara University Hospital, Istanbul Turkey
Defne Tamar Gurol, M.D.
Bakirkoy Mental Health and Research Hospital, Istanbul Turkey
Meral Berkem, M.D.
Marmara University Hospital, Istanbul Turkey
1.43
Neuropsychological Models Proposed to Explain ADHD
Tugba Bahadir, M.D.
Marmara University Hospital, Istanbul Turkey
Yanki Yazgan, M.D.
Marmara University Hospital, Istanbul Turkey
1.44
Anabolic Steroid Use among Iowa Youth: First Report of the Iowa Youth Survey
Gary R. Gaffney, M.D.
University of Iowa College of Medicine, Iowa City, IA
Stephan Arndt, Ph.D.
University of Iowa, Coralville, IA, IA
Vincent C. Gaffney
University of Iowa, Iowa City, IA
1.45
Do Adolescents with Bipolar Disorder Self-Medicate with Substances of Abuse?
Boris Lorberg, M.D.
Massachusetts General Hospital, Boston, MA
Timothy Wilens, M.D.
Massachusetts General Hospital, Boston, MA
Tiffany Parcell, B.S.
1.46
Comorbid Mood Disorders and Substance Use Disorders in Relation to Youth Suicide
Rodney R. Pinto, B.S.
Douglas Mental Health University Institute, McGill Group for Suicide Studies, McGill University, Montreal, ON
Monique Seguin, Ph.D.
Alain Lesage, FRCPC, M.D.
Gustavo Turecki, M.D., Ph.D.
Johanne Renaud, FRCPC, M.D., M.S.
Douglas Mental Health University Institute, Montreal, PQ
1.47
Co-Located Pediatric Mental Health Services: Perspectives from Social Workers
Karen J. Bos
Harvard Medical School and Harvard School of Public Health, Cambridge, MA
Eileen Dryden, Ph.D.
Institute for Community Health, Cambridge, MA
Deborah Weidner, M.D.
Cambridge Health Alliance, Boston, MA
Karen A. Hacker, M.D., M.P.H.
Institute for Community Health, Cambridge, MA
1.49
Amygdalar Enlargement in Adolescents with Major Depressive Disorder
Kathryn R. Cullen, M.D.
University of Minnesota, Minneapolis, MN
Bonnie Klimes-Dougan, Ph.D.
, Sherwood, MN
Ryan L. Muetzel, B.A.
Alaa K. Houri, B.A.
Susanne E. Jepsen, B.A.
Sanjiv Kumra, M.D.
, Woodbury, MN
1.50
Thyroid Alterations in Infant-Adolescent Psychiatric Pathology
Maria Gariup, M.D.
Hospital Clínico, Barcelona Spain
Astrid Morer, Ph.D.
Department of Child and Adolescent Psychiatry, Hospital Clínico, Barcelona Spain
Luisa Lázaro, M.D., Ph.D.
Hospital Clínico, Barcelona Spain
Josefina Castro, M.D., Ph.D.
Hospital Clínico, Barcelona Spain
1.51
London In-Patient Services Admissions for 2004-2007
Inmaculada Octavio, M.S.C.
Institute of Psychiatry, King's College London, London England
Ragnhild Banton
Southwark Primary Care Trust, London United Kingdom
Eric Taylor
MRC Child Psychiatry Unit, London England
1.52
Hyperactivity in Female Adolescent Population
Inmaculada Octavio, M.S.C.
Institute of Psychiatry, King's College London, London England
Eric Taylor
MRC Child Psychiatry Unit, London England
Susan J. Young, Ph.D.
Institute of Psychiatry, London United Kingdom
1.53
Moderating Effects of Parent-Child Interactions on Impairment in Hyperactive/Inattentive Preschoolers
Dione M. Healey, Ph.D.
University of Otago, Dunedin, Otago
Chaya B. Gopin, M.A.
, Teaneck, NJ
Bella R. Grossman, B.A.
Susan B. Campbell, Ph.D.
Jeffrey M. Halperin, Ph.D.
Queens College, City University of New York, Flushing, NY
1.54
Predictive Parameters for Methylphenidate Use and Compliance in Italian Children with ADHD: A 36 Months Follow-up
Paola Atzori, M.D.
Child Neuropsychiatry, Cagliari Italy
Tatiana Usala, M.D.
Fabrice Danjou, M.D.
Sara Carucci, M.D.
Alessandro Zuddas, M.D.
Department Neuroscience, University of Cagliari, Cagliari Italy
1.55
Once Daily Dexmethylphenidate Is Effective 30 Minutes Post-Dose in Children with ADHD: A Randomized, Double-Blind, Crossover Laboratory Classroom Study
Matthew Brams, M.D.
Baylor College of Medicine, Houston, TX
Alice R. Mao, M.D.
Baylor College of Medicineand Behavioral Sciences, Houston, TX
Kevin McCague, M.A.
Mary Borrello, R.N.
Rafael Muniz, M.D.
, Chester, NJ
1.56
Long-Term Safety and Tolerability of Atomoxetine Treatment in Children and Adolescents with ADHD: Follow-up to 4 Years
Craig L. Donnelly, M.D.
Dartmouth Medical School, Lebanon, NH
Paula T. Trzepacz, M.D.
Eli Lilly and Company, Indianapolis, IN
Mark Bangs, M.D.
, Indianapolis, IN
Ling Jin, M.D.
, Indianapolis, IN
Shuyu Zhang, M.S.
, Indianapolis, IN
Michael M. Witte, Ph.D.
Susan G. Ball, Ph.D.
Thomas J. Spencer, M.D.
, Boston, MA
1.57
Atomoxetine Treatment in Adults with ADHD and Comorbid Social Anxiety Disorder
Todd M. Durell, M.D.
Eli Lilly and Company, Indianapolis, IN
Michael Liebowitz, M.D.
William Kronenberger, Ph.D.
Richard L. Rubin, M.D.
Vermont Clinical Study Center, Burlington, VT
Meihua Qiao, M.S.
Millie Hollandbeck, B.S.
Kory Schuh, Ph.D.
Ahmed Deldar, Ph.D.
Lenard Adler, M.D.
New York University School of Medicine, New York, NY
1.58
Evaluation of the Safety, Tolerability, and Pharmacokinetic Profile of ABT-089 Following Administration of Escalating Single Oral Doses in Pediatric Subjects with ADHD
Tushar Garimella, Ph.D.
Abbott Laboratories, Abbott Park, IL
Wenzi Chiu, Ph.D.
Walid M. Abi-Saab, M.D.
Abbott Laboratories, Abbott Park, IL
Earle Bain, M.D.
, Libertyville, IL
Sandeep Dutta, Ph.D.
1.59
Once Daily Dexmethylphenidate in Children with ADHD: A Pooled Analysis of Early Onset of Efficacy
John M. Giblin, M.D.
Clinical Study Centers, LLC, Little Rock, AR
Mary Borrello, R.N.
Kevin McCague, M.A.
Rafael Muniz, M.D.
, Chester, NJ
1.60
Dopamine Transporter Genotype and Stimulant Side Effect Factors in ADHD Youth
Mark A. Stein, Ph.D.
Institute for Juvenile Research, Glencoe, IL
Reut Gruber, Ph.D.
Douglas Mental Health University Institute, McGill University, Montreal, PQ
Ridha Joober, M.D.
Natalie Grizenko, M.D.
Bennett L. Leventhal, M.D.
Institute for Juvenile Research, Chicago, IL
Edwin H. Cook Jr., M.D.
University of Illinois at Chicago, Chicago, IL
